Risk Factors of Porphyria Cutanea Tarda (PCT)

Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.

Single blood + urine sample uptake to investigate : mutations in HFE gene, uroporphyrinogen decarboxylase activity, HCV genotye, history of disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Porphyria Cutanea Tarda Blood-Borne Infections Communicable Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Flaviviridae Infections Genetic Diseases, Inborn Hemochromatosis Hepatitis Hepatitis C Hepatitis, Viral, Human Infections Iron Metabolism Disorders Iron Overload Liver Diseases Metabolic Diseases Metabolism, Inborn Errors Metal Metabolism, Inborn Errors Nutritional and Metabolic Diseases Porphyrias Porphyrias, Hepatic RNA Virus Infections Skin Diseases Skin Diseases, Genetic Skin and Connective Tissue Diseases Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Porphyria cutanea tarda /HCV negative Porphyria cutanea tarda/ HCV positive HCV positive HCV negative controls

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Official study title

"Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus"

Important dates

Study start: 1999
First posted: Sep 21, 2005
Registry last updated: Sep 21, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed